|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Cutsem E, Cervantes A, Nordlinger B
and Arnold D; ESMO Guidelines Working Group, : Metastatic
colorectal cancer: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 25 Suppl 3:iii1–iii9. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
de Gramont A, Bosset JF, Milan C, Rougier
P, Bouché O, Etienne PL, Morvan F, Louvet C, Guillot T, François E
and Bedenne L: Randomized trial comparing monthly low-dose
leucovorin and fluorouracil bolus with bimonthly high-dose
leucovorin and fluorouracil bolus plus continuous infusion for
advanced colorectal cancer: A French intergroup study. J Clin
Oncol. 15:808–815. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goldberg RM, Sargent DJ, Morton RF, Fuchs
CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts
SR: A randomized controlled trial of fluorouracil plus leucovorin,
irinotecan, and oxaliplatin combinations in patients with
previously untreated metastatic colorectal cancer. J Clin Oncol.
22:23–30. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tournigand C, André T, Achille E, Lledo G,
Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et
al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced
colorectal cancer: A randomized GERCOR study. J Clin Oncol.
22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yamazaki K, Nagase M, Tamagawa H, Ueda S,
Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T,
et al: Randomized phase III study of bevacizumab plus FOLFIRI and
bevacizumab plus mFOLFOX6 as first-line treatment for patients with
metastatic colorectal cancer (WJOG4407G). Ann Oncol. 27:1539–1546.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Petrelli F, Borgonovo K, Cabiddu M,
Ghilardi M, Lonati V, Maspero F, Sauta MG, Beretta GD and Barni S:
FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients
with advanced colorectal cancer: A pooled analysis of 29 published
trials. Clin Colorectal Cancer. 12:145–151. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Saltz LB, Clarke S, Díaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, et al: Bevacizumab in combination with oxaliplatin-based
chemotherapy as first-line therapy in metastatic colorectal cancer:
A randomized phase III study. J Clin Oncol. 26:2013–2019. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Y, Jatkoe T, Zhang Y, Mutch MG,
Talantov D, Jiang J, McLeod HL and Atkins D: Gene expression
profiles and molecular markers to predict recurrence of Dukes' B
colon cancer. J Clin Oncol. 22:1564–1571. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Eschrich S, Yang I, Bloom G, Kwong KY,
Boulware D, Cantor A, Coppola D, Kruhøffer M, Aaltonen L, Orntoft
TF, et al: Molecular staging for survival prediction of colorectal
cancer patients. J Clin Oncol. 23:3526–3535. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Notterman DA, Alon U, Sierk AJ and Levine
AJ: Transcriptional gene expression profiles of colorectal adenoma,
adenocarcinoma, and normal tissue examined by oligonucleotide
arrays. Cancer Res. 61:3124–3130. 2001.PubMed/NCBI
|
|
13
|
Wen WH, Bernstein L, Lescallett J,
Beazer-Barclay Y, Sullivan-Halley J, White M and Press MF:
Comparison of TP53 mutations identified by oligonucleotide
microarray and conventional DNA sequence analysis. Cancer Res.
60:2716–2722. 2000.PubMed/NCBI
|
|
14
|
Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ,
Ando A, Miyoshi Y, Maeda E, Noguchi S and Kato K: Prediction of
docetaxel response in human breast cancer by gene expression
profiling. J Clin Oncol. 23:422–431. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Del Rio M, Molina F, Bascoul-Mollevi C,
Copois V, Bibeau F, Chalbos P, Bareil C, Kramar A, Salvetat N,
Fraslon C, et al: Gene expression signature in advanced colorectal
cancer patients select drugs and response for the use of
leucovorin, fluorouracil, and irinotecan. J Clin Oncol. 25:773–780.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Estevez-Garcia P, Rivera F, Molina-Pinelo
S, Benavent M, Gómez J, Limón ML, Pastor MD, Martinez-Perez J,
Paz-Ares L, Carnero A and Garcia-Carbonero R: Gene expression
profile predictive of response to chemotherapy in metastatic
colorectal cancer. Oncotarget. 6:6151–6159. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li S, Lu X, Chi P and Pan J:
Identification of HOXB8 and KLK11 expression levels as potential
biomarkers to predict the effects of FOLFOX4 chemotherapy. Future
Oncol. 9:727–736. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miller AB, Hoogstraten B, Staquet M and
Winkler A: Reporting results of cancer treatment. Cancer.
47:207–214. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aras M, Erdil TY, Dane F, Gungor S, Ones
T, Dede F, Inanir S and Turoglu HT: Comparison of WHO RECIST 1.1,
EORTC, and PERCIST criteria in the evaluation of treatment response
in malignant solid tumors. Nucl Med Commun. 37:9–15.
2016.PubMed/NCBI
|
|
21
|
Khokher S, Qureshi MU and Chaudhry NA:
Comparison of WHO and RECIST criteria for evaluation of clinical
response to chemotherapy in patients with advanced breast cancer.
Asian Pac J Cancer Prev. 13:3213–3218. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choi JH, Ahn MJ, Rhim HC, Kim JW, Lee GH,
Lee YY and Kim IS: Comparison of WHO and RECIST criteria for
response in metastatic colorectal carcinoma. Cancer Res Treat.
37:290–293. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park JO, Lee SI, Song SY, Kim K, Kim WS,
Jung CW, Park YS, Im YH, Kang WK, Lee MH, et al: Measuring response
in solid tumors: Comparison of RECIST and WHO response criteria.
Jpn J Clin Oncol. 33:533–537. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gautier L, Cope L, Bolstad BM and Irizarry
RA: affy-analysis of Affymetrix GeneChip data at the probe level.
Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Leek JT, Johnson WE, Parker HS, Jaffe AE
and Storey JD: The sva package for removing batch effects and other
unwanted variation in high-throughput experiments. Bioinformatics.
28:882–883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu TT, Chen YF, Hastie T, Sobel E and
Lange K: Genome-wide association analysis by lasso penalized
logistic regression. Bioinformatics. 25:714–721. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cuyle PJ and Prenen H: Current and future
biomarkers in the treatment of colorectal cancer. Acta Clin Belg.
72:103–115. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Robin X, Turck N, Hainard A, Tiberti N,
Lisacek F, Sanchez JC and Müller M: pROC: An open-source package
for R and S+ to analyze and compare ROC curves. BMC Bioinformatics.
12:772011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stintzing S: Personalized treatment for
colorectal carcinomas. Dtsch Med Wochenschr. 142:1652–1659.
2017.(In German). PubMed/NCBI
|
|
32
|
Gustavsson B, Carlsson G, Machover D,
Petrelli N, Roth A, Schmoll HJ, Tveit KM and Gibson F: A review of
the evolution of systemic chemotherapy in the management of
colorectal cancer. Clin Colorectal Cancer. 14:1–10. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Iwamoto S, Takahashi T, Tamagawa H,
Nakamura M, Munemoto Y, Kato T, Hata T, Denda T, Morita Y, Inukai
M, et al: FOLFIRI plus bevacizumab as second-line therapy in
patients with metastatic colorectal cancer after first-line
bevacizumab plus oxaliplatin-based therapy: The randomized phase
III EAGLE study. Ann Oncol. 26:1427–1433. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bazarbashi S, Aljubran A, Alzahrani A,
Mohieldin A, Soudy H and Shoukri M: Phase I/II trial of
capecitabine, oxaliplatin, and irinotecan in combination with
bevacizumab in first line treatment of metastatic colorectal
cancer. Cancer Med. 4:1505–1513. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Heinemann V, von Weikersthal LF, Decker T,
Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller
C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI
plus bevacizumab as first-line treatment for patients with
metastatic colorectal cancer (FIRE-3): A randomised, open-label,
phase 3 trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Stremitzer S, Sebio A, Stintzing S and
Lenz HJ: Panitumumab safety for treating colorectal cancer. Expert
Opin Drug Saf. 13:843–851. 2014.PubMed/NCBI
|
|
37
|
Saridaki Z, Souglakos J and Georgoulias V:
Prognostic and predictive significance of MSI in stages II/III
colon cancer. World J Gastroenterol. 20:6809–6814. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Webber EM, Kauffman TL, O'Connor E and
Goddard KA: Systematic review of the predictive effect of MSI
status in colorectal cancer patients undergoing 5FU-based
chemotherapy. BMC Cancer. 15:1562015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nakanishi R, Kitao H, Fujinaka Y,
Yamashita N, Iimori M, Tokunaga E, Yamashita N, Morita M, Kakeji Y
and Maehara Y: FANCJ expression predicts the response to
5-fluorouracil-based chemotherapy in MLH1-proficient colorectal
cancer. Ann Surg Oncol. 19:3627–3635. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Simmer F, Venderbosch S, Dijkstra JR,
Vink-Börger EM, Faber C, Mekenkamp LJ, Koopman M, De Haan AF, Punt
CJ and Nagtegaal ID: MicroRNA-143 is a putative predictive factor
for the response to fluoropyrimidine-based chemotherapy in patients
with metastatic colorectal cancer. Oncotarget. 6:22996–23007. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Molina-Pinelo S, Carnero A, Rivera F,
Estevez-Garcia P, Bozada JM, Limon ML, Benavent M, Gomez J, Pastor
MD, Chaves M, et al: MiR-107 and miR-99a-3p predict chemotherapy
response in patients with advanced colorectal cancer. BMC Cancer.
14:6562014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Candy PA, Phillips MR, Redfern AD, Colley
SM, Davidson JA, Stuart LM, Wood BA, Zeps N and Leedman PJ:
Notch-induced transcription factors are predictive of survival and
5-fluorouracil response in colorectal cancer patients. Br J Cancer.
109:1023–1030. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mariadason JM, Arango D, Shi Q, Wilson AJ,
Corner GA, Nicholas C, Aranes MJ, Lesser M, Schwartz EL and
Augenlicht LH: Gene expression profiling-based prediction of
response of colon carcinoma cells to 5-fluorouracil and
camptothecin. Cancer Res. 63:8791–8812. 2003.PubMed/NCBI
|
|
44
|
Kursa MB and Rudnicki WR: Feature
selection with the boruta package. J Stat Soft. 36:1–13. 2010.
View Article : Google Scholar
|
|
45
|
Zhang Z and Huang J: Intestinal stem
cells-types and markers. Cell Biol Int. 37:406–414. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chang EY, Tsai SH, Shun CT, Hee SW, Chang
YC, Tsai YC, Tsai JS, Chen HJ, Chou JW, Lin SY and Chuang LM:
Prostaglandin reductase 2 modulates ROS-mediated cell death and
tumor transformation of gastric cancer cells and is associated with
higher mortality in gastric cancer patients. Am J Pathol.
181:1316–1326. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li FF, Yan P, Zhao ZX, Liu Z, Song DW,
Zhao XW, Wang XS, Wang GY and Liu SL: Polymorphisms in the CHIT1
gene: Associations with colorectal cancer. Oncotarget.
7:39572–39581. 2016.PubMed/NCBI
|
|
48
|
Chang YT, Yeh YS, Ma CJ, Huang CW, Tsai
HL, Huang MY, Cheng TL and Wang JY: Optimization of a multigene
biochip for detection of relapsed and early relapsed colorectal
cancer. J Surg Res. 220:427–437. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jun S, Jung YS, Suh HN, Wang W, Kim MJ, Oh
YS, Lien EM, Shen X, Matsumoto Y, McCrea PD, et al: LIG4 mediates
Wnt signalling-induced radioresistance. Nat Commun. 7:109942016.
View Article : Google Scholar : PubMed/NCBI
|
